Lantern Pharma and Oregon partner to develop cancer treatment [Yahoo! Finance]
Lantern Pharma Inc. (LTRN)
Company Research
Source: Yahoo! Finance
XCE853 is an inhibitor of protein disulfide isomerase (PDI). The partnership will utilise RADR AI platform of Lantern to identify biomarkers and efficacy-linked signatures of XCE853 for precision development across solid tumours. Furthermore, this alliance will identify biomarker signatures that can aid in stratifying tumours that are most responsive to the drug and facilitate in the clinical development and patient selection in the future. Oregon focuses on developing XCE853 for a range of cancer indications, including drug-resistant ovarian and pancreatic cancers, certain haematological cancers, and several paediatric cancers, such as central nervous system (CNS) cancers. The collaboration aims to harness computational tools, including machine learning and large-scale molecular analysis, to streamline the development process. The partnership will integrate and interrogate a vast array of molecular, genetic, and transcriptomic data related to XCE853. RADR's extensive lib
Show less
Read more
Impact Snapshot
Event Time:
LTRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LTRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LTRN alerts
High impacting Lantern Pharma Inc. news events
Weekly update
A roundup of the hottest topics
LTRN
News
- Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights [Yahoo! Finance]Yahoo! Finance
- Lantern Pharma Reports First Quarter 2024 Financial Results and Business HighlightsBusiness Wire
- Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism [Yahoo! Finance]Yahoo! Finance
- Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer MetabolismBusiness Wire
- Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET [Yahoo! Finance]Yahoo! Finance
LTRN
Earnings
- 5/9/24 - Miss
LTRN
Analyst Actions
- 4/25/24 - HC Wainwright
LTRN
Sec Filings
- 5/9/24 - Form 8-K
- 5/9/24 - Form 10-Q
- 5/3/24 - Form ARS
- LTRN's page on the SEC website